Literature DB >> 21392703

What can anorexia nervosa teach us about appetite regulation?

Mark D DeBoer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21392703      PMCID： PMC3062266          DOI： 10.1016/j.nut.2011.02.001

Source DB:  PubMed          Journal:  Nutrition        ISSN： 0899-9007            Impact factor:   4.008


× No keyword cloud information.
  20 in total

1.  Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa.

Authors:  Natacha Germain; Bogdan Galusca; Dominique Grouselle; Delphine Frere; Stephane Billard; Jacques Epelbaum; Bruno Estour
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

2.  Pleasure for visual and olfactory stimuli evoking energy-dense foods is decreased in anorexia nervosa.

Authors:  Tao Jiang; Robert Soussignan; Daniel Rigaud; Benoist Schaal
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

Review 3.  Ghrelin: a potential therapeutic target for cancer.

Authors:  Dimitrios Nikolopoulos; Stamatis Theocharis; Gregory Kouraklis
Journal:  Regul Pept       Date:  2010-04-09

4.  Ghrelin reactive autoantibodies in restrictive anorexia nervosa.

Authors:  Mutsumi Terashi; Akihiro Asakawa; Toshiro Harada; Miharu Ushikai; Quentin Coquerel; Maria Hamze Sinno; Pierre Déchelotte; Akio Inui; Sergueï O Fetissov
Journal:  Nutrition       Date:  2011-04       Impact factor: 4.008

Review 5.  Eating disorders.

Authors:  Janet Treasure; Angélica M Claudino; Nancy Zucker
Journal:  Lancet       Date:  2010-02-13       Impact factor: 79.321

6.  Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment.

Authors:  Damien R Ashby; Heather E Ford; Katie J Wynne; Alison M Wren; Kevin G Murphy; Mark Busbridge; Edwina A Brown; David H Taube; Mohammad A Ghatei; Frederick W K Tam; Stephen R Bloom; Peter Choi
Journal:  Kidney Int       Date:  2009-04-22       Impact factor: 10.612

7.  Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.

Authors:  Mark D Deboer; Xinxia Zhu; Peter R Levasseur; Akio Inui; Zhaoyong Hu; Guofeng Han; William E Mitch; John E Taylor; Heather A Halem; Jesse Z Dong; Rakesh Datta; Michael D Culler; Daniel L Marks
Journal:  Endocrinology       Date:  2007-11-26       Impact factor: 4.736

8.  Insulin binding to antibodies is a risk factor for inexplicable severe hypoglycaemia in children with type-1 diabetes mellitus.

Authors:  O Seewi; C Jaeger; R G Bretzel; E Schönau
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-05       Impact factor: 2.949

Review 9.  Emergence of ghrelin as a treatment for cachexia syndromes.

Authors:  Mark Daniel DeBoer
Journal:  Nutrition       Date:  2008-09       Impact factor: 4.008

10.  Autoantibodies against appetite-regulating peptide hormones and neuropeptides: putative modulation by gut microflora.

Authors:  Sergueï O Fetissov; Maria Hamze Sinno; Moïse Coëffier; Christine Bole-Feysot; Philippe Ducrotté; Tomas Hökfelt; Pierre Déchelotte
Journal:  Nutrition       Date:  2008-02-08       Impact factor: 4.008
View more
  2 in total

Review 1.  The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.

Authors:  Mark D DeBoer
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Neuropeptide B and Vaspin as New Biomarkers in Anorexia Nervosa.

Authors:  Teresa Grzelak; Marta Tyszkiewicz-Nwafor; Agata Dutkiewicz; Aniceta Ada Mikulska; Monika Dmitrzak-Weglarz; Agnieszka Slopien; Krystyna Czyzewska; Elzbieta Paszynska
Journal:  Biomed Res Int       Date:  2018-06-10       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.